Checks and balances on cholinergic signaling in brain and body function

Trends in Neurosciences

Volumn 38, Issue 7, 2015, Pages 448-458

  Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Acetylcholine signaling; MiRNA regulation; Noncoding SNPs; Post transcriptional changes

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; MICRORNA; MESSENGER RNA;

ADDICTION; ALCOHOLISM; ALLELE; ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; ANXIETY; BRAIN FUNCTION; CELL DIFFERENTIATION; CELL MATURATION; CELL SPECIFICITY; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN GENOME PROJECT; MENTAL STRESS; MULTIGENE FAMILY; NONHUMAN; PARASYMPATHETIC FUNCTION; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SYNAPTIC MEMBRANE; TOBACCO DEPENDENCE; ANIMAL; BIOLOGICAL MODEL; BRAIN; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ANIMALS; BRAIN; CHOLINERGIC AGENTS; HUMANS; MODELS, BIOLOGICAL; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84933670342     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2015.05.007     Document Type: Review

References (100)

1. Dale H. The action of certain esters and ethers of choline, and their relation to muscarine. J. Pharmacol. Exp. Ther. 1914, 6:147-190.
2. Loewi O., Navratil E. Über humorale Übertragbarkeit der Herznervenwirkung. X. Mitteilung. Pflugers Arch. 1926, 214:678-688. (in German).
3. Changeux J.P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat. Rev. Neurosci. 2010, 11:389-401.
4. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. Goodman and Gilman's the Pharmacological Basis of Therapeutics 2006, 217-236. McGraw-Hill. 11th edn. L.L. Brunton (Ed.).
5. Dani J.A., De Biasi M. Mesolimbic dopamine and habenulo-interpeduncular pathways in nicotine withdrawal. Cold Spring Harb. Perspect. Med. 2013, 3:a012138.
6. Grando S.A. Connections of nicotine to cancer. Nat. Rev. Cancer 2014, 14:419-429.
7. Picciotto M.R., et al. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 2012, 76:116-129.
8. Darvesh S., et al. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 2003, 4:131-138.
9. Soreq H., Seidman S. Acetylcholinesterase - new roles for an old actor. Nat. Rev. Neurosci. 2001, 2:294-302.
10. Kolisnyk B., et al. Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex. J. Neurosci. 2013, 33:14908-14920.
11. Albuquerque E.X., et al. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 2009, 89:73-120.
12. Ruiz de Azua I., et al. Critical metabolic roles of beta-cell M3 muscarinic acetylcholine receptors. Life Sci. 2012, 91:986-991.
13. Okuda T., et al. Identification and characterization of the high-affinity choline transporter. Nat. Neurosci. 2000, 3:120-125.
14. Moussaieff A., et al. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab. 2015, 21:392-402.
15. Paez-Gonzalez P., et al. Identification of distinct ChAT neurons and activity-dependent control of postnatal SVZ neurogenesis. Nat. Neurosci. 2014, 17:934-942.
16. Renier N., et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 2014, 159:896-910.
17. Cho H.H., et al. Isl1 directly controls a cholinergic neuronal identity in the developing forebrain and spinal cord by forming cell type-specific complexes. PLoS Genet. 2014, 10:e1004280.
18. Huang T., et al. Tlx3 controls cholinergic transmitter and peptide phenotypes in a subset of prenatal sympathetic neurons. J. Neurosci. 2013, 33:10667-10675.
19. Jensen M., et al. Wnt signaling regulates acetylcholine receptor translocation and synaptic plasticity in the adult nervous system. Cell 2012, 149:173-187.
20. Jiang L., et al. Optogenetic studies of nicotinic contributions to cholinergic signaling in the central nervous system. Rev. Neurosci. 2014, 25:755-771.
21. Morishita H., et al. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. Science 2010, 330:1238-1240.
22. Fu X.W., et al. The ly-6 protein, Lynx1, is an endogenous inhibitor of nicotinic signaling in airway epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 303:L661-L668.
23. Gu Z., et al. Cholinergic coordination of presynaptic and postsynaptic activity induces timing-dependent hippocampal synaptic plasticity. J. Neurosci. 2012, 32:12337-12348.
24. Navarrete M., et al. Astrocytes mediate in vivo cholinergic-induced synaptic plasticity. PLoS Biol. 2012, 10:e1001259.
25. Mitsushima D., et al. A cholinergic trigger drives learning-induced plasticity at hippocampal synapses. Nat. Commun. 2013, 4:2760.
26. Takata N., et al. Astrocyte calcium signaling transforms cholinergic modulation to cortical plasticity in vivo. J. Neurosci. 2011, 31:18155-18165.
27. Michalk A., et al. Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders. Am. J. Hum. Genet. 2008, 82:464-476.
28. Sabatelli M., et al. Rare missense variants of neuronal nicotinic acetylcholine receptor altering receptor function are associated with sporadic amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009, 18:3997-4006.
29. Sciamanna G., et al. Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA. Neurobiol. Dis. 2012, 47:416-427.
30. Muller J.S., et al. CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn. Brain 2006, 129:2784-2793.
31. Shen X.M., et al. Myasthenic syndrome AChR alpha C-loop mutant disrupts initiation of channel gating. J. Clin. Invest. 2012, 122:2613-2621.
32. Berry A.S., et al. Disposed to distraction: genetic variation in the cholinergic system influences distractibility but not time-on-task effects. J. Cogn. Neurosci. 2014, 26:1981-1991.
33. English B.A., et al. Choline transporter gene variation is associated with attention-deficit hyperactivity disorder. J. Neurodev. Disord. 2009, 1:252-263.
34. Neumann S.A., et al. Human choline transporter gene variation is associated with corticolimbic reactivity and autonomic-cholinergic function. Biol. Psychiatry 2006, 60:1155-1162.
35. Threlfell S., et al. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 2012, 75:58-64.
36. Cachope R., et al. Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing. Cell Rep. 2012, 2:33-41.
37. Chuhma N., et al. Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron 2014, 81:901-912.
38. Wieland S., et al. Phasic dopaminergic activity exerts fast control of cholinergic interneuron firing via sequential NMDA, D2, and D1 receptor activation. J. Neurosci. 2014, 34:11549-11559.
39. Yang Y., et al. Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:12078-12083.
40. Mineur Y.S., et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3573-3578.
41. Wu M., et al. SLEEPLESS is a bifunctional regulator of excitability and cholinergic synaptic transmission. Curr. Biol. 2014, 24:621-629.
42. Lima J.K., et al. 1914G variant of BCHE gene associated with enzyme activity, obesity and triglyceride levels. Gene 2013, 532:24-26.
43. Rosas-Ballina M., et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011, 334:98-101.
44. Shaked I., et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 2009, 31:965-973.
45. Guyenet P.G. The sympathetic control of blood pressure. Nat. Rev. Neurosci. 2006, 7:335-346.
46. Sun M., et al. Reduced nicotinic receptor function in sympathetic ganglia is responsible for the hypothermia in the acetylcholinesterase knockout mouse. J. Physiol. 2007, 578:751-764.
47. Toda N., Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacol. Rev. 2003, 55:271-324.
48. + dendritic cells in human tonsils and potentiates lymphocytic cholinergic activity. J. Neuroimmunol. 2014, 267:43-49.
49. Song P., et al. Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis. J. Neurochem. 2013, 126:451-461.
50. Howard T.D., et al. Evaluation of candidate genes for cholinesterase activity in farmworkers exposed to organophosphorus pesticides: association of single nucleotide polymorphisms in BCHE. Environ. Health Perspect. 2010, 118:1395-1399.
51. Kaufer D., et al. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998, 393:373-377.
52. Sussman J.L., et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253:872-879.
53. Hibbs R.E., et al. Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal α7 nicotinic acetylcholine receptor. EMBO J. 2009, 28:3040-3051.
54. Bansal A., et al. Choline phosphorylation and regulation of transcription of choline kinase alpha in hypoxia. J. Lipid Res. 2012, 53:149-157.
55. Zhou G., et al. Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2). J. Biol. Chem. 2013, 288:11940-11948.
56. Slimak M.A., et al. Habenular expression of rare missense variants of the β4 nicotinic receptor subunit alters nicotine consumption. Front. Hum. Neurosci. 2014, 8:12.
57. Berrettini W.H., Doyle G.A. The CHRNA5-A3-B4 gene cluster in nicotine addiction. Mol. Psychiatry 2012, 17:856-866.
58. Fowler C.D., et al. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011, 471:597-601.
59. Greenbaum L., Lerer B. Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions. Mol. Psychiatry 2009, 14:912-945.
60. Wang J.C., et al. Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol. Psychiatry 2009, 14:501-510.
61. Frahm S., et al. Aversion to nicotine is regulated by the balanced activity of β4 and α5 nicotinic receptor subunits in the medial habenula. Neuron 2011, 70:522-535.
62. Henderson B.J., et al. Nicotine exploits a COPI-mediated process for chaperone-mediated up-regulation of its receptors. J. Gen. Physiol. 2014, 143:51-66.
63. Giacobini E., Gold G. Alzheimer disease therapy - moving from amyloid-β to Tau. Nat. Rev. Neurol. 2013, 9:677-686.
64. Gray S.L., et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern. Med. 2015, 175:401-407.
65. De Gois S., et al. Is RE1/NRSE a common cis-regulatory sequence for ChAT and VAChT genes?. J. Biol. Chem. 2000, 275:36683-36690.
66. Sailaja B.S., et al. Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E3687-E3695.
67. Meshorer E., Soreq H. Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci. 2006, 29:216-224.
68. Nadorp B., Soreq H. Predicted overlapping microRNA regulators of acetylcholine packaging and degradation in neuroinflammation-related disorders. Front. Mol. Neurosci. 2014, 7:9.
69. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
70. Londin E., et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:E1106-E1115.
71. Hanin G., et al. Competing targets of microRNA-608 affect anxiety and hypertension. Hum. Mol. Genet. 2014, 23:4569-4580.
72. Barbash S., et al. Global coevolution of human microRNAs and their target genes. Mol. Biol. Evol. 2014, 31:1237-1247.
73. Lau P., et al. Alteration of the microRNA network during the progression of Alzheimer's disease. EMBO Mol. Med. 2013, 5:1613-1634.
74. Shaltiel G., et al. Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. Brain Struct. Funct. 2013, 218:59-72.
75. Tracey K.J. Immune cells exploit a neural circuit to enter the CNS. Cell 2012, 148:392-394.
76. Maharshak N., et al. MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease. Inflamm. Bowel Dis. 2013, 19:1346-1353.
77. The Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
78. Waiskopf N., et al. Quantum dot labeling of butyrylcholinesterase maintains substrate and inhibitor interactions and cell adherence features. ACS Chem. Neurosci. 2011, 2:141-150.
79. Soreq H., Wolf Y. NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mol. Med. 2011, 17:548-555.
80. Anagnostaras S.G., et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 2003, 6:51-58.
81. Hamilton S.E., et al. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13311-13316.
82. Goldberg J.A., et al. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat. Neurosci. 2012, 15:1414-1421.
83. Perrier A.L., et al. PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 2002, 33:275-285.
84. Engel A.G., et al. Further observations in congenital myasthenic syndromes. Ann. N. Y. Acad. Sci. 2008, 1132:104-113.
85. Harel M., et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:9031-9035.
86. Golomb B.A. Acetylcholinesterase inhibitors and Gulf War illnesses. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4295-4300.
87. Inestrosa N.C., et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16:881-891.
88. Berson A., et al. Changes in readthrough acetylcholinesterase expression modulate amyloid-β pathology. Brain 2008, 131:109-119.
89. Ballard C., et al. The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of Tau in dementia patients. Dement. Geriatr. Cogn. Disord. 2005, 19:357-360.
90. Sussman J., et al. Further developments with antisense treatment for myasthenia gravis. Ann. N. Y. Acad. Sci. 2012, 1275:13-16.
91. Zimmerman G., et al. Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NFκB pathway. Transl. Psychiatry 2012, 2:e78.
92. Nadorp B., Soreq H. Gut feeling: microRNA discriminators of the intestinal TLR9-cholinergic links. Int. Immunopharmacol. 2015, Published online May 20, 2015. 10.1016/j.intimp.2015.04.058.
93. Lakhan S.E., Kirchgessner A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J. Transl. Med. 2011, 9:129.
94. Li F., et al. The protective effect of PNU-282987, a selective α7 nicotinic acetylcholine receptor agonist, on the hepatic ischemia-reperfusion injury is associated with the inhibition of high-mobility group box 1 protein expression and nuclear factor κB activation in mice. Shock 2013, 39:197-203.
95. Belgard T.G., Geschwind D.H. Retooling spare parts: gene duplication and cognition. Nat. Neurosci. 2013, 16:6-8.
96. Gaugler T., et al. Most genetic risk for autism resides with common variation. Nat. Genet. 2014, 46:881-885.
97. Fromer M., et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014, 506:179-184.
98. Ashwal-Fluss R., et al. circRNA biogenesis competes with pre-mRNA splicing. Mol. Cell 2014, 56:55-66.
99. Jens M., Rajewsky N. Competition between target sites of regulators shapes post-transcriptional gene regulation. Nat. Rev. Genet. 2015, 16:113-126.
100. Hou D., et al. Proteomics screen to reveal molecular changes mediated by C722G missense mutation in CHRM2 gene. J. Proteomics 2013, 89:39-50.